Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + BR in Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT02747732Phase 2Unknown
- Start
- Dec 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBL), transformed indolent lymphoma (TIL). Status: unknown.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBL)transformed indolent lymphoma (TIL)
Beyond the preview
Go deeper on NCT02747732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02747732.